Latest Updates in GI Cancer
HERIZON-GEA-01: Zanidatamab Plus Chemotherapy ± Tislelizumab Advances First-Line Treatment in HER2-Positive Gastroesophageal Adenocarcinoma
HERIZON-GEA-01 is a pivotal phase III trial evaluating zanidatamab-based regimens, with or without the PD-1 inhibitor tislelizumab, compared with trastuzumab...
Phase III COMMIT Study Shows Promising Frontline Approach for dMMR/MSI-H Metastatic Colorectal Cancer
The phase III COMMIT trial demonstrates that intensifying first-line immunotherapy with chemotherapy and antiangiogenic therapy can substantially improve outcomes for...
BREAKWATER Cohort 3: Early Integration of Encorafenib–Cetuximab Plus FOLFIRI Improves Response in BRAF V600E mCRC
Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) represent a biologically distinct subgroup with historically poor outcomes and limited first-line,...
Perioperative Durvalumab Plus FLOT Improves Survival in Resectable Gastric and GEJ Cancer
The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with FLOT chemotherapy as the first and only perioperative immunotherapy for...
Zanzalintinib Plus Atezolizumab Improves Survival in Refractory MSS Metastatic Colorectal Cancer
Patients with refractory metastatic colorectal cancer (mCRC) and microsatellite-stable (MSS) disease have limited treatment options and historically derive minimal benefit...
From ‘Undruggable’ to Breakthrough: Pan-RAS Inhibitors Transform GI Oncology Practice
Pan-RAS inhibitors like RMC-6236 are showing unprecedented 30% response rates in previously treated pancreatic cancer, potentially ending the decades-long frustration...
Latest in Bile Duct Cancer (Cholangiocarcinoma)
Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results
Camrelizumab plus chemoradiation improved 3-year OS to 58.2% vs 30.5% observation in resected cholangiocarcinoma/gallbladder cancer.
Latest in Colorectal Cancer
Phase III COMMIT Study Shows Promising Frontline Approach for dMMR/MSI-H Metastatic Colorectal Cancer
The phase III COMMIT trial demonstrates that intensifying first-line immunotherapy with chemotherapy and antiangiogenic therapy can substantially improve outcomes for...
BREAKWATER Cohort 3: Early Integration of Encorafenib–Cetuximab Plus FOLFIRI Improves Response in BRAF V600E mCRC
Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) represent a biologically distinct subgroup with historically poor outcomes and limited first-line,...
Zanzalintinib Plus Atezolizumab Improves Survival in Refractory MSS Metastatic Colorectal Cancer
Patients with refractory metastatic colorectal cancer (mCRC) and microsatellite-stable (MSS) disease have limited treatment options and historically derive minimal benefit...
SAKK 41/13 Trial: Adjuvant Aspirin Shows Promise in PIK3CA-Mutant Colon Cancer
First randomized trial shows aspirin 100mg daily improves disease-free survival in PIK3CA-mutant colon cancer patients.
Distinct Genomic Mutation Patterns Identified in Early-Onset Colorectal Cancer: International Multi-Cohort Analysis
EOCRC exhibited significantly higher TMB compared with LOCRC in hypermutated tumors, with distinct gene mutation patterns including elevated APC and...
Colorectal Cancer Screening Uptake Increases Following USPSTF Guidelines for Ages 45-49
CRC screening in ages 45-49 jumped from 20.8% to 33.7% post-USPSTF guidelines, but gains limited to educated, insured populations.
Latest in Upper GI/Gastroesophageal Cancer
HERIZON-GEA-01: Zanidatamab Plus Chemotherapy ± Tislelizumab Advances First-Line Treatment in HER2-Positive Gastroesophageal Adenocarcinoma
HERIZON-GEA-01 is a pivotal phase III trial evaluating zanidatamab-based regimens, with or without the PD-1 inhibitor tislelizumab, compared with trastuzumab...
Perioperative Durvalumab Plus FLOT Improves Survival in Resectable Gastric and GEJ Cancer
The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with FLOT chemotherapy as the first and only perioperative immunotherapy for...
From ‘Undruggable’ to Breakthrough: Pan-RAS Inhibitors Transform GI Oncology Practice
Pan-RAS inhibitors like RMC-6236 are showing unprecedented 30% response rates in previously treated pancreatic cancer, potentially ending the decades-long frustration...
Making Sense of FLOT, Durvalumab, and the Role of Real-World Tumor Biology
Total neoadjuvant therapy with FLOT may optimize outcomes, but ctDNA could guide personalized treatment decisions.
Latest in Hepatocellular Carcinoma
FDA Approves Radioembolization Therapy for Liver Cancer
Y-90 microspheres achieved 98.5% response rate and 100% local tumor control in unresectable HCC patients across multicenter trial.
Latest in Pancreatic Cancer
From ‘Undruggable’ to Breakthrough: Pan-RAS Inhibitors Transform GI Oncology Practice
Pan-RAS inhibitors like RMC-6236 are showing unprecedented 30% response rates in previously treated pancreatic cancer, potentially ending the decades-long frustration...
PurIST® Algorithm Validated for Pancreatic Cancer First-Line Therapy Selection in Landmark Real-World Study
Real-world evidence demonstrates PurIST's ability to guide first-line treatment decisions and improve outcomes for patients.
Targeting ‘Undruggable’ KRAS in Pancreatic Cancer: Clinical Breakthroughs and Resistance Strategies
KRASG12C inhibitors achieve 21-33% response rates with superior safety vs standard chemo in PDAC patients.
MicroRNA Liquid Biopsy Panel Achieves 97% Accuracy for Pancreatic Cancer Early Detection
"Even in the earlier stages of PDAC, these markers are about 91% accurate. And when we use them together with...
Latest in Gallbladder Cancer
Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results
Camrelizumab plus chemoradiation improved 3-year OS to 58.2% vs 30.5% observation in resected cholangiocarcinoma/gallbladder cancer.